Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By
Noshin Noorjahan
-
0
18
Investigators evaluated zongertinib in a multicohort, phase Ia–Ib trial involving patients with advanced or metastatic HER2-mutant NSCLC.
[New England Journal of Medicine]
Abstract